Predictive role of single nucleotide polymorphisms of MTHFR and ABCG2 genes in the response to first-line chemotherapy in advanced colorectal cancer

Jing ZHAO,Wen ZHANG,Wen-hua LI,Zhe ZHANG,Dan ZHU,Qi-he YU,Wei-jian GUO,Jin LI

DOI: https://doi.org/10.3781/j.issn.1000-7431.2012.09.008

2012-01-01

Tumor

Abstract:Objective: To investigate the predictive role of single nucleotide polymorphisms (SNPs) of methylenetetrahydrofolate reductase (MTHFR) and breast cancer resistance protein (BCRP/ABCG2) in the response to first-line chemotherapy in advanced colorectal cancer. Methods: The DNA sequencing technique was used to detect the SNPs of MTHFR 677C>T, MTHFR 1298A>C, MTHFR ABCG2 34G>A and MTHFR 421C>A in peripheral blood from 154 patients with advanced colorectal cancer receiving FOLFOX, XELOX or FOLFIRI regimen as first-line chemotherapy, and the relationships of SNPs with early response, progression-free survival (PFS) and overall survival (OS) were analyzed. Results: The overall response rate of first-line chemotherapy in 154 patients was 31.8%, and the median PFS and OS were 8.1 and 30.7 months, respectively. There was no significant correlation of MTHFR and ABCG2 SNPs with early response and OS (P > 0.05). Patients carrying 3-4 favorable genotypes (MTHFR 677C/C, MTHFR 1298A/A, ABCG2 34G/A or A/A and ABCG2 421C/A or A/A) had a longer median PFS than those carrying 0-2 favorable genotypes (9.8 vs 7.5 months, P = 0.013). COX multivariate analysis revealed that the factors of number of favorable genotypes (P = 0.017) and radical resection of primary lesion (P = 0.010) were independent factors for PFS. Both univariate and multivariate analyses showed that OS was independently associated with radical resection of primary lesion (both P ﹦ 0.000). Conclusion: Combined detection of MTHFR and ABCG2 SNPs may play a role in predicting PFS of patients with advanced colorectal cancer receiving first-line chemotherapy. Radical resection of primary lesion is an independent prognostic factor for both PFS and OS.